GlassScriptPhysician profile
Mason Henehan
NPI 1093275117
$5,414.00
in general payments reported to CMS, 2019-2025
18 companies · $3,588 in 2025
The $3,588 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $986 · 2024: $840 · 2025: $3,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,455 · Food and Beverage: $1,859 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,455.00 |
| Food and Beverage | $1,859.01 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,991.87 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.08 | 2023-2024 | Sotyktu |
| Pfizer INC. | $160.95 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.02 | 2023-2024 | Spevigo |
| Janssen Biotech, INC. | $141.81 | 2023-2024 | Tremfya |
| Dermavant Sciences, INC. | $109.11 | 2023-2024 | Vtama |
| Incyte Corporation | $93.52 | 2023-2024 | Opzelura |
| Abbvie INC. | $63.67 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $56.95 | 2023-2024 | Dupixent |
| Lilly USA, LLC | $43.90 | 2024 | Taltz |
| Ucb, INC. | $38.92 | 2023-2024 | Cimzia |
| Galderma Laboratories, L.P. | $35.46 | 2023-2024 | Aklief |
| Novartis Pharmaceuticals Corporation | $34.62 | 2023 | |
| Arcutis Biotherapeutics, INC. | $22.83 | 2023 | |
| Amgen INC. | $22.33 | 2024 | Otezla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $19.67 | 2023 | Nuzyra |
| Sun Pharmaceutical Industries INC. | $16.61 | 2023 | Blu-U |
| Biofrontera INC. | $11.68 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mason Henehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.